Novo Nordisk - Search News

Insider Monkey on MSN · 2h

Why Did Novo Nordisk (NVO) Go Down on Friday?

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other firms that took a hit on Friday.

The Motley Fool · 12h

Is Novo Nordisk Stock a Buy?

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching $39.3 billion, thanks to its portfolio of potent drugs for cardiometabolic illnesses like diabetes and obesity.

Business Insider · 1d

Argus Research Remains a Buy on Novo Nordisk (NVO)

In a report released yesterday, Jasper Hellweg from Argus Research maintained a Buy rating on Novo Nordisk (NVO – Research Report). The

Investing.com on MSN · 1d

BofA reiterates Buy on Novo Nordisk shares on performance

BofA Securities maintained a Buy rating on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) with a price target of DKK1,075.00. The firm's analyst commented on the stock's recent performance, noting a significant downturn in the second half of 2024,

1don MSN

Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

1don MSN

US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

1d

Novo Nordisk CEO attends crisis talks with Danish PM amid Donald Trump Greenland threats

Bosses from Fortune 500 Europe companies including Novo Nordisk, Lego, and Carlsberg met with the PM as Trump ups his threats ...

2d

Novo Nordisk, Other Firms Meet Danish PM to Discuss Trump Tariff Threats

Denmark's Prime Minister Mette Frederiksen had summoned business leaders after speaking on Wednesday with U.S.

1don MSN

Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

1d

Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

1d

LVMH overtakes Novo Nordisk as Europe’s most valuable company

Luxury bellwether regains crown as drugmaker slips on concerns it will have to cut weight loss medication prices in US ...

2d

Finally An Attractive Entry Point Into Novo Nordisk

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

1d

Novo Nordisk's Ozempic & Wegovy in 2027 Medicare price talks

GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along ...

1d

E-sellers of compounded weight-loss drugs fail to reveal risks, research shows

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results